NEW TECH FOODS

Verley, a French food biotechnology company specialising in functional dairy proteins via precision fermentation, has received a 'No Questions Letter' from the US Food and Drug Administration (FDA), confirming the safety of its ingredients for food use. The clearance positions Verley for a US commercial launch in 2026 and supports its plans for global expansion. The FDA letter covers two of Verley’s flagship proteins: FermWhey Native  – a whey protein composed of 95% β-lactoglobulin, supporting performance and recovery in sports and active nutrition. FermWhey MicroStab  – a patented, microparticulated protein offering thermal and pH stability for complex formulations like ready-to-drink beverages. Verley is said to be the first company worldwide to receive FDA clearance for dairy ingredients made via precision fermentation and enhanced with functionalisation. The 'No Questions Letter' confirms the agency reviewed Verley’s submission and found no safety concerns under the proposed conditions of use. The milestone follows Verley’s self-affirmed GRAS designation earlier in 2025 and strengthens confidence among US customers, retailers and manufacturers exploring advanced protein solutions. Precision fermentation allows the production of pure, functional dairy proteins without animals, complementing conventional dairy while improving sustainability and functionality. Hélène Briand, co-founder and chief innovation and commercial officer at Verley, said: "This is a major regulatory validation for our science and technology. Receiving the FDA’s 'No Questions' Letter is not only a milestone for Verley, it’s a signal that precision fermentation is ready to scale and complement conventional dairy, delivering nutritional performance with fewer resources." "This is just the beginning," added Stéphane Mac Millan, CEO of Verley. "With other geographies in motion and a growing demand for sustainable proteins, we’re proud to set a global benchmark in safety, performance, and trust. And here’s something we’re especially proud of: We received this regulatory clearance just three years after founding the company, a testament to the clarity, speed and execution of our scientific and commercial roadmap." Top image: © Verley

CANZA, the Canadian Alliance for Net-Zero Agri-food, has unveiled the Million Acre Challenge, a new initiative to expand regenerative farming practices across Canada. The programme launches with a $7 million contribution from the Weston family, part of their $50 million commitment to regenerative agriculture. The challenge aims to help farmers adopt economically viable and environmentally sustainable practices through cost-sharing incentives, agronomic support and access to an online portal of public and private programmes. Nick Betts, CANZA's executive director, said: "It's time to recognise and reward farmers for the value they create – for people, climate and nature – through regenerative farming practices. The Million Acre Challenge is about everyone collaborating together, across the full value chain, to scale these practices on the ground." The initiative begins in Southwestern Ontario’s cornbelt, targeting farmers in their first two cohorts. Participating farms will implement a range of regenerative practices, tailored to individual operations, to further reduce carbon emissions in supply chains including beef, corn, wheat and other livestock. Galen Weston, chairman of Loblaw Companies, added: "Farmers are core to Canadian prosperity, and our national resilience requires sustainable practices that create value across the agricultural supply chain. We're proud to make this contribution to launch the Million Acre Challenge as part of our family's $50 million commitment towards regenerative agriculture in Canada." The programme plans to expand nationally over time, supporting existing participants while recruiting new farmers annually, with a goal to scale regenerative practices exponentially through 2030 and beyond.

It’s easy to get caught up in the news and activities of the industry’s global giants, but what about the smaller firms pushing boundaries with bold ideas? In this instalment of start-up spotlight – which celebrates lesser-known companies and their innovations – we speak to Dafna Gabbay, co-founder and CEO of Finally Foods, an AI-driven molecular farming start-up. Dafna Gabbay Can you tell us about the inspiration behind Finally Foods and how the idea of growing dairy proteins in potatoes came about? The idea came from an unmet need in the alternative protein space: while demand for dairy alternatives is growing, there was no viable method for producing the most essential milk proteins – like casein – at scale, cost-effectively and with full functionality. Precision fermentation faces limitations with complex proteins, and traditional dairy is resource-intensive and not sustainable over time. Our vision was to use plants as natural bioreactors, and we identified the potato as a powerful, underutilised host for this purpose. Your field trial is taking place less than a year after launch – what key factors have enabled such rapid progress? A few things enabled this pace: first, our exclusive license to a proprietary AI platform allowed us to design the casein and optimise the genetic modifications of the potato efficiently. Second, the deep experience of our R&D team – especially in plant science and AI – allowed us to move quickly from lab to field. Lastly, we’ve had strong alignment with our partners from day one, enabling focused execution. Molecular farming is often seen as a long-term bet due to regulatory hurdles. How are you navigating these challenges, and what do you see as the biggest regulatory roadblocks ahead? We’re targeting geographies with clearer regulatory pathways for GMO cultivation, including the Canada, LATAM, Australia and finally the US. We also separate the regulatory track for cultivation from that of the extracted protein, which helps streamline planning. The main challenges ahead involve ensuring food safety approval for novel proteins and navigating varying GMO-related rules across markets. We’re working closely with regulatory experts to design a global strategy from the outset. Potatoes were chosen as the ‘bioreactors’ for your casein production. What makes them more suitable than other plant-based expression systems? Potatoes offer several advantages: they’re genetically well-characterised, relatively simple to modify and already used for protein extraction at scale. They offer high biomass yield per hectare allowing for at least two growing seasons per year. Importantly, we’ve also developed a cost-effective extraction protocol specifically for casein from potatoes, which improves feasibility at scale. You’re already in discussions with dairy companies – what kind of response have you had from industry players, and what are the next steps towards commercialisation? The response has been very positive and there is further news that I'll be able to share in a few months time. Traditional dairy companies are actively seeking sustainable alternatives, but they want solutions that don’t compromise on taste, texture or functionality. Our casein delivers on those expectations. We’ve secured multiple letter of intents and are moving toward joint development agreements to test and tailor our casein for specific dairy applications. Scaling up is a major challenge for food-tech start-ups. What lessons have you learned so far about bringing molecular farming to a commercial level? The key is to design for scale from the start. We chose a crop with a scalable extraction process that uses existing infrastructure. Another lesson is that commercialisation requires deep collaboration with customers – early engagement through JDAs is critical to tailor the ingredient and ensure successful adoption. How does AI enhance your molecular farming approach, and what advantages has it provided in terms of efficiency and scalability? Our AI platform helps us identify the optimal gene constructs and expression sites in the plant genome, reducing the trial-and-error phase dramatically. It also enables better prediction of protein functionality and expression levels. This shortens R&D cycles and helps us scale faster, as we can iterate and optimise with greater precision and speed. There’s an ongoing debate around ultra-processed foods and consumer perception of novel food technologies. How do you plan to communicate the benefits of your potato-based casein to consumers? We emphasise that our casein is molecularly identical to the protein found in milk, with no foreign DNA in the final product. The production process is transparent and avoids synthetic additives. We plan to communicate benefits through our B2B partners by highlighting functionality, sustainability and simplicity – real dairy protein, just made in plants. What advice would you give to other start-ups looking to break into the cultivated food space, especially those working with novel protein production methods? We’re still early in our journey, but one lesson so far is the importance of focusing on the real pain points in the industry, not just the technological novelty. Building a team that combines scientific expertise with business and regulatory understanding is also critical. Most of all, staying close to potential customers from day one helps ensure you're developing something that truly fits into the value chain and solves a real need. Finally, what’s next for Finally Foods? Where do you see the company in the next five years? Our next milestones are scaling up casein production and entering product validation with commercial dairy partners. In five years, we will prove the commercial viability of molecular farming for casein, establish an impressive portfolio of strategic industry collaborations and start expanding into additional proteins and geographies.

Biotech company Checkerspot has partnered with Huvepharma to commercialise a new microalgae-derived oil that replicates key nutritional fats found in human milk, which is said to be a potential game-changer for the infant formula industry. The collaboration will bring high sn-2 palmitate algal oil to industrial scale, offering a sustainable and consistent alternative to palm-derived oils currently used in infant nutrition. The ingredient is designed to mimic the triglyceride structures in human milk fat, which play an essential role in nutrient absorption and digestive comfort for infants. Unlike existing products that rely on palm oil and enzymatic modification, Checkerspot’s oil is produced directly through fermentation of microalgae using simple sugars. This process eliminates dependence on palm-based feedstocks, reduces environmental impact and ensures a highly controlled and contamination-free ingredient. Kiril Domuschiev, president and CEO of Huvepharma, said: “Checkerspot’s breakthrough high sn-2 palmitate algal oil is a leap forward for infant nutrition, both in terms of nutritional quality and environmental impact. Huvepharma’s deep expertise in fermentation at scale and global market presence, ideally positions the partnership to deliver this innovation reliably and competitively to the infant nutrition industry." The partnership combines Checkerspot’s proprietary molecular and strain engineering technology with Huvepharma’s established manufacturing and distribution capabilities. Together, the companies aim to meet growing demand for more sustainable and high-performance fats and oils in infant formula and advanced nutrition. John Krzywicki, CEO of Checkerspot, added: “Partnering with Huvepharma allows us to bring high sn-2 palmitate algal oil to industrial scale and make it accessible to infant formula brands worldwide. This is a key milestone in redefining how high-performance fats and oils for nutrition are sourced and produced." The companies plan to position algal oil as a scalable, palm-free solution to the infant formula industry’s sustainability and supply challenges, supporting manufacturers looking to more closely replicate the nutritional profile of human milk fat.

Asterix Foods has emerged from stealth with $4.2 million in seed funding to scale a new, low-cost alternative to precision fermentation. The round was led by CPT Capital, with participation from ReGen Ventures, SOSV, Grok Ventures and the Israeli Innovation Authority. Precision fermentation has become central to food and biotech innovation, enabling the production of high-value bioactive proteins through genetically engineered microbes. However, the process is notoriously expensive to scale, building a single facility can cost between $125 million and $500 million in capital expenditure. Asterix says it has developed a more affordable and flexible approach. Instead of modifying microbes, the company uses plant cell suspension cultures grown in Massively Parallel Modular Bioreactors (MPMB). This set-up, the company claims, can cut facility costs by over 95%, shorten development timelines from years to months and eliminate the need for costly cleanrooms, while maintaining or even improving protein yield and functionality. Dan Even, CEO of Asterix Foods, said: “Bioactivity makes these proteins so powerful for the food industry, unlocking new applications in food, nutrition and health. Our system shows how future production facilities can be deployed quickly, flexibly, and at dramatically lower cost.” Because plant cells are multicellular and equipped to produce complex proteins like glycoproteins, they offer an advantage over microbial systems, which often struggle with such molecules and require stringent contamination controls. Asterix’s platform uses plant cells that are naturally more resistant to contamination, allowing safe operation in simpler bioreactors that can be housed in standard food manufacturing environments. The company’s pilot facility in central Tel Aviv, Israel, demonstrates how this flexibility works in practice. Its modular bioreactors can run year-round, continuously, without the extensive downtime typical of precision fermentation plants. They also consume less energy and water by operating at room temperature and avoiding sterilization cycles. Harry Kalms, investor at CPT Capital, commented: “Asterix’s capex-light and modular system gives them and their customers flexibility to locate production exactly where it’s needed. CPT has long supported removing animals from the supply chain but what’s exciting now is the clear pull from the market." "Companies are recognising the limits of today’s protein supply chain and looking for ways to produce high-value, bioactive proteins at a fraction of the cost, and at unprecedented volumes.” Po Bronson, general partner at SOSV, added: “Plant cell suspension cultures are already used by global corporations for vaccines and food pigments. Asterix is now pushing this platform further, opening new opportunities to produce alternative proteins with unprecedented cost-efficiency and precision.” With its technology validated across multiple proteins, Asterix is now partnering with corporates to target ingredients critical to future food supply chains. The new funding will be used to expand its Tel Aviv pilot site and begin delivering samples to customers.

UK agritech firm Straw Innovations has launched a rice farming machine designed to boost yields, cut emissions and strengthen food security in Asia. The launch marks a major step in its expansion into the Philippines, Indonesia and India. The machine, called the Straw Traktor, has been shown to increase rice production by up to 65% a year while halving methane emissions, one of agriculture’s most potent greenhouse gases. It enables farmers to harvest rice three times a year instead of two, while improving soil health and generating new income streams from what was once treated as waste. The Straw Traktor was officially unveiled at the Rice Straw Bioenergy Hub (RSBH) in Pila, Laguna, Philippines – the first facility of its kind globally. Developed by Straw Innovations, in partnership with Aston University, SEARCA, Koolmill Systems and funded by Innovate UK, the hub demonstrates how rice straw can be transformed into biochar, renewable energy, compost and livestock bedding. Representatives from the British Embassy Manila, the Philippine Department of Agriculture (DA) and local government officials attended the launch, underscoring growing international collaboration on sustainable agriculture. Rice is a staple for over half the world’s population, with 90% produced in Asia. But extreme weather, population growth and inefficient farming methods have strained production and intensified the climate impact of rice cultivation. Paddy fields are a major source of methane – a gas more than 80 times more potent than CO₂ – largely due to the burning and decomposition of leftover straw. Founder and director of Straw Innovations, Craig Jamieson, said: "This new system brings together world-leading technologies and business models for the first time to set a new benchmark for rice processing globally. For rice-producing communities and the environment, it’s nothing short of transformational.” The Straw Traktor works in flooded conditions, collecting straw from fields and rotavating the soil to prepare for the next planting. It also spreads biochar, a soil amendment that boosts fertility and carbon sequestration, raising yields by an additional 10%. The machine’s design caters to smallholder farmers, offering a high return on investment through added revenue from upcycled products. At the RSBH, Straw Innovations’ solution is integrated with Koolmill’s energy-efficient rice milling technology, Takachar’s Takavator biochar system, and the Biogas Hub, forming a low-emission model for sustainable rice production. Research by Aston University and SEARCA will assess the system’s socio-economic and environmental impacts, helping to scale the approach across Asia. The roll-out of the Straw Traktor in Indonesia and India is being supported by Innovate UK, UKAid and Takachar under the Energy Catalyst programme, with launches planned for next year. Economic and climate counsellor at British Embassy Manila, Lloyd Cameron, added: “Businesses which treat climate risks as opportunities will define the markets of the future. When UK science meets Philippine innovation, rice straw becomes more than a byproduct, it becomes part of the solution. That partnership lies at the core of the Rice Straw Bioenergy Hub: harnessing new technology, developing local business models and increasing productivity.” SEARCA center director Mercedita Sombilla commented: "Aligned with SEARCA’s mission to empower farmers, the development of rice straw management solutions will not only contribute to reduction of greenhouse gas emissions but also enable communities to turn agricultural wastes into livelihood opportunities that increase incomes". "The promotion of policy-backed innovative technologies and strategies indeed help drive the use of climate smart practices that are beneficial to agriculture and environment."

Japan is set to host a major international symposium on cultivated food regulation next month, as the government nears the release of its first-ever guidelines for cell-based products. The event – Japan Cell-Ag-Ready Dialogue 2025 – will take place on 13-14 November in Tokyo, gathering policymakers, scientists and industry leaders to debate how Japan should govern the emerging cultivated food sector. Organised by the Japan Association for Cellular Agriculture (JACA) in partnership with The University of Tokyo’s Research Center for Advanced Science and Technology (RCAST) and government agencies, the two-day hybrid symposium comes at a pivotal moment for the country’s food innovation agenda. The event will open with a keynote from a Consumer Affairs Agency official overseeing Japan’s cultivated food policy, followed by government-commissioned experts from the National Institute of Health Sciences and the Tokyo University of Agriculture discussing risk assessment frameworks for novel foods. Regulatory specialists from Singapore, the US, Europe, Australia and China will join a panel to compare global approaches to safety evaluation and oversight of cultivated foods, a discussion expected to help inform Japan’s evolving Novel Food framework. The second day will turn to the perspectives of Japanese stakeholders, including consumer groups, a former Nikkei journalist specialising in food safety and Wagyu producers collaborating with US-based Eat Just, which is said to be one of the first companies to commercialise cultivated chicken. The agenda also includes experts on misinformation and food risk communication. International participants from the Good Food Institute, Carnegie Mellon University, Roslin Technologies, Safe Food Advocacy Europe, Hoxton Farms, BlueNalu and others are expected to contribute insights on technology, regulation and market readiness.

New Wave Biotech has partnered with the Centre for Process Innovation (CPI) to apply hybrid AI-powered simulations to one of industrial biotechnology’s most persistent challenges: lipid extraction. The collaboration will also explore intracellular bioprocesses, aiming to improve scalability across a range of applications. Lipids, key ingredients in products from food and feed to cosmetics and pharmaceuticals, are seeing growing demand. In the UK, concerns over food security are rising, with the Office for National Statistics reporting a 5.1% increase in food prices over the past year. More efficient lipid processing could help reduce costs, strengthen supply chains and improve sustainability for both industry and consumers. Current extraction methods, however, have long presented challenges. Solvent-based techniques, while widely used, rely on large volumes of toxic and flammable chemicals and require energy-intensive recovery. Non-solvent approaches are safer but remain expensive and inconsistent, limiting the scale-up of sustainable alternatives to palm oil, cocoa butter and animal fat substitutes. Through the partnership, New Wave Biotech will provide CPI with its hybrid AI platform to optimise both solvent and non-solvent lipid extraction. By running thousands of in-silico simulations, the platform can assess performance, cost and sustainability trade-offs before laboratory trials, helping companies scale more efficiently. Nix Hall, CTO of New Wave Biotech, said:  “We’re excited to work with CPI to optimise lipid bioprocesses, which are essential for scaling many of the next generation of sustainable products. Lipid costs are visible in everything from food to cosmetics, and solving this challenge is key to making alternatives affordable and accessible". "By combining predictive accuracy with techno-economic and sustainability insights, our platform helps innovators cut down on trial and error and move faster towards solutions that benefit both industry and consumers.” Stephen Wright, manager of downstream processing at CPI, added: “Partnering with New Wave Biotech gives us powerful new tools to help clients scale sustainable products. Unlike many AI/ML tools that need huge datasets, this platform achieves high accuracy from minimal data, allowing us to identify the best downstream routes much earlier and with greater confidence.”

Italian food ingredients company Foreverland has opened its first production facility in Puglia, Southern Italy, to produce its flagship cocoa-free chocolate alternative, Choruba. Choruba is made from Mediterranean crops such as carob, pumpkin seeds and chickpeas. The cocoa-free alternative aims to replicate the indulgent flavour and texture of chocolate while reducing environmental impact. By decreasing reliance on cocoa, it also offers manufacturers a way to manage supply volatility, price fluctuations and climate-related pressures. The plant is expected to produce over 500 tonnes of the ingredient annually, which is designed to help food manufacturers navigate cocoa market challenges and meet sustainability targets. The new facility is part of Foreverland’s growth strategy, allowing the company to scale production, run industrial trials with larger clients and serve small and medium-sized businesses. A dedicated pilot fermentation room will enable the team to refine processes, protect proprietary know-how and validate production economics. Alongside the plant opening, Foreverland announced a new retail partnership with Italian protein company Small Giants. The collaboration has produced Choruba Protein Bites, peanut butter and chocolate-flavoured snacks made with Small Giants’ yeast-based protein and coated with Choruba. The vegan, high-protein snacks are priced at €3.29 for a three-pack or €1.99 for a single bar and are available online and in Gulliver supermarkets across Italy. Massimo Sabatini, co-founder and CEO of Foreverland, said: “The launch of our Puglia facility marks the moment Foreverland moves from pilot projects to full-scale production". "The new plant allows us to work hand in hand with manufacturers, speed up recipe development and bring sustainable chocolate alternatives into everyday products across Europe – all while ensuring we can meet demand at accessible price points. Our partnership with Small Giants is a strong example of this next phase, showing how sustainable chocolate alternatives are ready for the mainstream.” Edoardo Imparato, CEO of Small Giants, added: “Retailers and consumers are looking for real alternatives in categories like chocolate, where sustainability challenges are growing. Through our collaboration with Foreverland, we’re bringing products made with innovative ingredients to market shelves. They deliver on taste, nutrition and responsibility. It’s a concrete step towards making sustainable indulgence the new normal in European supermarkets.” Foreverland is also exploring expansion into France and the Nordics, building on its current presence in Italy and Germany.

Alt-dairy start-up Climax Foods has rebranded to Bettani Farms; has appointed former Califia Farms CFO, Sandeep Patel, as CEO and chairman; and has raised $6.5 million in Series A funding. Bettani, based in California, US, has developed a protein-rich, non-GMO ingredient platform that is also free from dairy, soy and nuts, for use in plant-based cheese products. Its proprietary protein ingredient, Caseed, is made from regenerative seed crops and mimics the functionality and mouthfeel of dairy casein while remaining 100% plant-based and free from common allergens. According to Bettani, the ingredient’s creamy texture, neutral flavour profile and white colour make it ideally suited for developing a range of protein-rich, dairy-free alternative to popular cheeses like mozzarella, feta, goat’s cheese, cream cheese, brie and blue. It can offer 12-20g of protein per 100g of cheese. Additionally, the start-up said its natural, farm-sourced ingredient can provide a more cost competitive alternative to fermentation-based casein equivalents. The funding round was led by S2G Investments, a multi-stage investment firm focused on scaling solutions across food and agriculture, energy and oceans. It also saw participation from new and existing investors including At One Ventures, Gratitude Railroad, Manta Ray Ventures and Toba Capital. New CEO Patel joins Bettani from Califia Farms, with other previous experience including a role as president and CFO of PopSockets. Sandeep Patel He also brings extensive industry experience across packaged food, agriculture, consumer products and sustainable technologies from his time as a managing director at Goldman Sachs and Barclays, where he advised food industry leaders, entrepreneurs and investors. Under his leadership, Bettani will focus on commercialising Caseed and Caseed-powered cheeses in partnership with frozen food makers, foodservice operators and existing dairy-free cheese brands seeking to improve their formulations. Patel commented: “Bettani is poised to do for pizza what oat milk has done for coffee. Just as oat won coffee over the last five years with its superior taste, mouthfeel, performance and allergen profile, our Caseed-powered cheeses deliver the melt, stretch, texture and flavour consumers crave in pizza and other hot foods – without the allergens and high carbon footprint of dairy.” Sanjeev Krishnan, managing partner at S2G, said: “As Bettani starts this new chapter, we believe it’s clear the company has the strong leadership and vision needed to make protein-rich, dairy-free cheeses commonplace”. “We’re proud to continue to support Bettani and the commercialisation of its technology at a critical time when demand for protein-rich, allergen-free and more sustainable food products is increasing.”

ImpacFat, a Singapore-based company developing stem-cell derived omega-3 fish fat, has announced its expansion into Japan, establishing a research and operational presence in Tokyo. The company signed an agreement with JR East to set up its facilities at Link Scholar’s Hub (LiSH) in Takanawa Gateway City. ImpacFat aims to develop functional ingredients rich in DHA and EPA and expand their use in food, supplements and cosmeceuticals while contributing to sustainable food innovation in Japan. This marks ImpacFat’s first move outside Singapore. The company plans to work closely with local researchers, industry partners and stakeholders to advance cell-cultured technology for food, supplements and cosmetics. Japan’s seafood and health supplement markets make it a key target as the global omega-3 ingredient market is projected to surpass $8 billion by 2030, said the company. ImpacFat also announced the close of a strategic investment round with Japanese and regional partners, including Toyo Seikan Group, 144 Ventures (Leave a Nest Group) and Lin Xiangliang, CEO of Esco Aster. The investments will support the company’s technology commercialisation and cross-border research initiatives. Mandy Hon, CEO and co-founder of ImpacFat, said: “Expanding into Japan is a defining moment for ImpacFat. Japan has long been a global leader in food innovation, and we are honoured to work alongside Toyo Seikan Group, Leave a Nest and our other Japanese partners to build a sustainable cultivated food ecosystem." "By establishing our presence in Takanawa Gateway City, we hope to connect science, innovation and sustainability to create meaningful impact for both Singapore and Japan.” Takuji Nakamura, president of Toyo Seikan Grou, said: “We believe that ImpacFat’s development of functional ingredients derived from fish fat cells, rich in nutrients such as DHA and EPA, can meet the rising global awareness of food security and the growing demand for healthy and delicious food". "Toyo Seikan Group will leverage its core technologies in sterilisation and moisture/gas barrier to build, together with ImpacFat, a value chain that maximises the potential of cell-cultured fish fat. With our cross-border ecosystem partners, we aim to accelerate this movement under the concept of refine in Japan, test in Singapore, and launch into the Asian market.”

DSM-Firmenich Animal Nutrition & Health has entered a strategic partnership with FarmTrace, a global farm connection and analytics platform, to simplify the way environmental data is collected and processed on farms. The agreement integrates DSM-Firmenich’s "environmental footprinting solution," Sustell, with FarmTrace’s platform, automating the flow of farm-level information. The move aims to reduce the need for manual inputs and questionnaires, which have often been barriers to scaling sustainability reporting. According to the companies, the integration will make sustainability measurement more accessible and consistent, allowing farmers and supply chains to expand reporting across large networks of farms. David Nickell, VP of sustainability and business solutions at DSM-Firmenich Animal Nutrition & Health, said: “Farmers are being asked to do more than ever, and sustainability shouldn’t add complexity. Through our partnership with FarmTrace, we are enabling end-to-end integration of accurate, real-time farm data into Sustell, so we can focus on what we do best: translating data into actionable insights that drive environmental improvement.” Katherine Zambaldi, CEO of FarmTrace, added: “Sustainable food systems need scalable solutions. By linking our data infrastructure with Sustell, we’re helping unlock value from existing farm technology and enabling sustainability insights without adding administrative burdens.” "By eliminating the friction of time-consuming manual data collection, the integration between FarmTrace and Sustell saves farmers time, makes sustainability measurement more accessible and consistent, and enables supply chains to scale environmental reporting across hundreds or thousands of farms. This marks a significant step in DSM-Firmenich’s mission to make measurable sustainability a practical reality for every farm, everywhere.”